BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31915016)

  • 1. Bevacizumab treatment of meningeal melanoma metastases.
    Simonsen TG; Gaustad JV; Rofstad EK
    J Transl Med; 2020 Jan; 18(1):13. PubMed ID: 31915016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.
    Schuster C; Akslen LA; Straume O
    PLoS One; 2016; 11(5):e0155242. PubMed ID: 27166673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
    Yang H; Jager MJ; Grossniklaus HE
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
    Leenders WP; Küsters B; Verrijp K; Maass C; Wesseling P; Heerschap A; Ruiter D; Ryan A; de Waal R
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6222-30. PubMed ID: 15448011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer.
    Peng CL; Lin HC; Chiang WL; Shih YH; Chiang PF; Luo TY; Cheng CC; Shieh MJ
    Photodiagnosis Photodyn Ther; 2018 Sep; 23():111-118. PubMed ID: 29894822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
    Rofstad EK; Halsør EF
    Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
    Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
    Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic Molecules Suppressed Meningioma-Induced Neovascularization: A Corneal Angiogenesis Study.
    Tatarli N; Ceylan D; Oksal MD; Avsar T; Kilic T
    Turk Neurosurg; 2022; 32(5):786-792. PubMed ID: 35929040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy.
    Schuster C; Akslen LA; Stokowy T; Straume O
    J Pathol Clin Res; 2019 Jan; 5(1):53-62. PubMed ID: 30225999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intertumor heterogeneity in vascularity and invasiveness of artificial melanoma brain metastases.
    Simonsen TG; Gaustad JV; Rofstad EK
    J Exp Clin Cancer Res; 2015 Dec; 34():150. PubMed ID: 26667022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
    Eguchi R; Kawabe JI; Wakabayashi I
    J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
    Bannoud N; Stupirski JC; Cagnoni AJ; Hockl PF; Pérez Sáez JM; García PA; Mahmoud YD; Gambarte Tudela J; Scheidegger MA; Marshall A; Corrie PG; Middleton MR; Mariño KV; Girotti MR; Croci DO; Rabinovich GA
    Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2214350120. PubMed ID: 36634146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Fane ME; Ecker BL; Kaur A; Marino GE; Alicea GM; Douglass SM; Chhabra Y; Webster MR; Marshall A; Colling R; Espinosa O; Coupe N; Maroo N; Campo L; Middleton MR; Corrie P; Xu X; Karakousis GC; Weeraratna AT
    Clin Cancer Res; 2020 Nov; 26(21):5709-5719. PubMed ID: 33097493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.